Evidence map›Paper›PMID 26285063›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2015

Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin.

Lei Miao, Yuhua Wang, C Michael Lin, Yang Xiong, Naihan Chen, Lu Zhang, William Y Kim, Leaf Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Lei MiaoDivision of Molecular Pharmaceutics and Center of Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Yuhua WangDivision of Molecular Pharmaceutics and Center of Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
C Michael LinDivision of Molecular Pharmaceutics and Center of Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Yang XiongDivision of Molecular Pharmaceutics and Center of Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; School of Pharmacy, Zhejiang Chinese Medical University, 310053, China.
Naihan ChenDivision of Molecular Pharmaceutics and Center of Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Lu ZhangDivision of Molecular Pharmaceutics and Center of Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
William Y KimLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Leaf HuangDivision of Molecular Pharmaceutics and Center of Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: leafh@unc.edu.
University of North Carolina at Chapel Hill · US

Funding

Translational Nanosystems for Improved Lung Cancer Treatment with Small MoleculesU54CA151652 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAROON, ZISHAN A, TEPPER, JOEL E · 2010 to 2014
$12.1M
Hepatic Non-viral Gene TherapyR01DK100664 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, LEAF · 2013 to 2017
$1.7M
Nanocrystals for the Treatment of Multidrug Resistance in CancerR01CA149387 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, LEAF · 2011 to 2015
$1.5M
Novel nanoparticles for siRNA deliveryR01CA149363 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, LEAF · 2010 to 2014
$1.3M
NCI NIH HHS CA149363NCI NIH HHS CA149387NCI NIH HHS CA151652NCI NIH HHS R01 CA149363NCI NIH HHS R01 CA149387NCI NIH HHS U54 CA151652NIDDK NIH HHS DK100664NIDDK NIH HHS R01 DK100664
6 · The paper itself

Abstract

The tumor microenvironment (TME) serves as a multidrug resistant center for tumors under the assault of chemotherapy and a physiological barrier against the penetration of therapeutic nanoparticles (NPs). Previous studies have indicated the ability for therapeutic NP to distribute into, and deplete tumor-associated fibroblasts (TAFs) for improved therapeutic outcomes. However, a drug resistant phenotype gradually arises after repeated doses of chemotherapeutic NP. Herein, the acquisition of drug resistant phenotypes in the TME after repeated cisplatin NP treatment was examined. Particularly, this study was aimed at investigating the effects of NP damaged TAFs on neighboring cells and alteration of stromal structure after cisplatin treatment. Findings suggested that while off-targeted NP damaged TAFs and inhibited tumor growth after an initial dose, chronic exposure to cisplatin NP led to elevated secretion of Wnt16 in a paracrine manner in TAFs. Wnt16 upregulation was then attributed to heightened tumor cell resistance and stroma reconstruction. Results attest to the efficacy of Wnt16 knockdown in damaged TAFs as a promising combinatory strategy to improve efficacy of cisplatin NP in a stroma-rich bladder cancer model.

Indexed as

NanoparticlesAnimalsAntineoplastic AgentsCell Line, TumorCells, CulturedCisplatinCoculture TechniquesDrug Resistance, NeoplasmFemaleHumansHuman Umbilical Vein Endothelial CellsMiceMice, Inbred BALB CMice, NudeNIH 3T3 CellsRNA, Small InterferingAntineoplastic AgentsCisplatinRNA, Small InterferingWNT16 protein, humanWnt16 protein, mouseWnt ProteinsCisplatinNanoparticleTumor associated fibroblastTumor microenvironmentWnt16

Identifiers

PMID26285063
PMCPMC4623876
OpenAlexW1440506460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.